{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:48Z","timestamp":1740123348128,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008028","name":"School of Medicine and Public Health, University of Wisconsin-Madison","doi-asserted-by":"publisher","award":["Grant P30 CA014520"],"award-info":[{"award-number":["Grant P30 CA014520"]}],"id":[{"id":"10.13039\/100008028","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10637-020-00929-y","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T20:02:36Z","timestamp":1586203356000},"page":"1520-1525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase 1 dose escalation trial of TAS-102 (trifluridine\/tipiracil) and temozolomide in the treatment of advanced neuroendocrine tumors"],"prefix":"10.1007","volume":"38","author":[{"given":"Nataliya V.","family":"Uboha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam J.","family":"Lubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle K.","family":"LoConte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Mulkerin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens C.","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin A.","family":"Deming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"929_CR1","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/ijc.24943","volume":"126","author":"IV Bijnsdorp","year":"2010","unstructured":"Bijnsdorp IV, Peters GJ, Temmink OH, Fukushima M, Kruyt FA (2010) Differential activation of cell death and autophagy results in an increased cytotoxic potential for trifluorothymidine compared to 5-fluorouracil in colon cancer cells. Int J Cancer 126:2457\u20132468","journal-title":"Int J Cancer"},{"key":"929_CR2","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","volume":"30","author":"JA Chan","year":"2012","unstructured":"Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH (2012) Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963\u20132968","journal-title":"J Clin Oncol"},{"key":"929_CR3","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<944::AID-CNCR8>3.0.CO;2-P","volume":"86","author":"PN Cheng","year":"1999","unstructured":"Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944\u2013948","journal-title":"Cancer"},{"key":"929_CR4","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad S, Sundin A, Janson ET et al (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986\u20132991","journal-title":"Clin Cancer Res"},{"key":"929_CR5","first-page":"545","volume":"13","author":"T Emura","year":"2004","unstructured":"Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K (2004) A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 13:545\u2013549","journal-title":"Int J Mol Med"},{"key":"929_CR6","first-page":"571","volume":"25","author":"T Emura","year":"2004","unstructured":"Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M (2004) A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 25:571\u2013578","journal-title":"Int J Oncol"},{"key":"929_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","volume":"71","author":"RL Fine","year":"2013","unstructured":"Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA, Mowatt KB, Dinnen RD, Mao Y, Stevens PD, Schrope B, Allendorf J, Lee JA, Sherman WH, Chabot JA (2013) Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 71:663\u2013670","journal-title":"Cancer Chemother Pharmacol"},{"key":"929_CR8","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","volume":"22","author":"MA Kouvaraki","year":"2004","unstructured":"Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762\u20134771","journal-title":"J Clin Oncol"},{"key":"929_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke MH, Shah MH, Benson AB 3rd et al (2015) Neuroendocrine tumors, version 1.2015. J Natl Compr Cancer Netw 13:78\u2013108","journal-title":"J Natl Compr Cancer Netw"},{"key":"929_CR10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1200\/JCO.2005.03.6046","volume":"24","author":"MH Kulke","year":"2006","unstructured":"Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401\u2013406","journal-title":"J Clin Oncol"},{"key":"929_CR11","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.2018.36.15_suppl.4004","volume":"36","author":"PL Kunz","year":"2018","unstructured":"Kunz PL, Catalano PJ, Nimeiri H et al (2018) A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer research group (E2211). J Clin Oncol 36:4004\u20134004","journal-title":"J Clin Oncol"},{"key":"929_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919","journal-title":"N Engl J Med"},{"key":"929_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/01.coc.0000135343.06038.eb","volume":"27","author":"AD Mccollum","year":"2004","unstructured":"Mccollum AD, Kulke MH, Ryan DP et al (2004) Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27:485\u2013488","journal-title":"Am J Clin Oncol"},{"key":"929_CR14","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","volume":"303","author":"CG Moertel","year":"1980","unstructured":"Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189\u20131194","journal-title":"N Engl J Med"},{"key":"929_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1056\/NEJM199202203260804","volume":"326","author":"CG Moertel","year":"1992","unstructured":"Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519\u2013523","journal-title":"N Engl J Med"},{"key":"929_CR16","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yal\u00e7\u0131n \u015e, Fujitani K, Beretta GD, Cutsem EV, Winkler RE, Makris L, Ilson DH, Tabernero J (2018) Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 19:1437\u20131448","journal-title":"Lancet Oncol"},{"key":"929_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2307\/2531693","volume":"45","author":"BE Storer","year":"1989","unstructured":"Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925\u2013937","journal-title":"Biometrics"},{"key":"929_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2217\/fon.15.276","volume":"12","author":"N Uboha","year":"2016","unstructured":"Uboha N, Hochster HS (2016) TAS-102: a novel antimetabolite for the 21st century. Future Oncol 12:153\u2013163","journal-title":"Future Oncol"},{"key":"929_CR19","doi-asserted-by":"crossref","unstructured":"Yoshino T, Mayer R, Falcone A et al. (2014) Results of a Multiceneter, randomized, double-blind, phase III study of TAS-102 vs. placebo, with best supportive care, in patients with metastatic colorectal cacner refractory to standard therapies (RECOURSE). Ann Oncol 25:abstract O-0022","DOI":"10.1093\/annonc\/mdu193.22"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00929-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00929-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00929-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T14:39:54Z","timestamp":1722695994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00929-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00929-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"28 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Relevant conflicts of interest\/competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethical standards"}},{"value":"This study was performed after approval by an institutional review board and in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}